I-Revaprazan Hydrochloride CAS 178307-42-1 Assay ≥99.0% API Factory High Purity
Igama Lekhemikhali: I-Revaprazan Hydrochloride;I-Revaprazan HCL
I-CAS: 178307-42-1
Ikhwalithi ephezulu ye-API, Ukukhiqiza Kwezentengiso
Igama Lekhemikhali | I-Revaprazan Hydrochloride |
Omqondofana | I-Revaprazan HCL |
Inombolo ye-CAS | 178307-42-1 |
Inombolo yeCAT | I-RF-API48 |
Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
I-Molecular Formula | I-C22H24ClFN4 |
Isisindo samangqamuzana | 398.904 |
Ibhrendi | I-Ruifu Chemical |
Into | Imininingwane |
Ukubukeka | I-Crystalline Powder Emhlophe noma Engamhlophe |
Ukuncibilika | Incibilika ngokukhululekile ku-chloroform, i-dichlormeth;Incibilika ku-acetic acid;Incibilika kancane ku-methanol, i-DMSO;Ayincibiliki ku-acetone, i-ACN;Cishe ayincibiliki kusixazululo se-NaOH esingu-0.1mol/L.Isixazululo se-HCL esingu-0.1mol/L. |
Ukuhlonza | Kufanele kuphendulwe kahle λ max 271nm, 205nm IR |
I-Melting Point | 219.0~222.0℃ |
Ukucaca Nombala | Kufanele icace futhi ingabi nambala ku-dichlormeth |
I-Chloride | ≤8.93% |
Ukungcola Okukodwa | ≤0.10% |
Ukungcola Okuphelele | ≤0.50% |
Ukulahlekelwa Ekumisweni | ≤0.50% |
Izinsalela ekushiseni | ≤0.10% |
I-sulfate | ≤20ppm |
I-Arsenic | ≤10ppm |
Izinsimbi Ezisindayo | ≤10ppm |
Isivivinyo | ≥99.0% |
Izinga Lokuhlola | I-Enterprise Standard |
Ukusetshenziswa | I-Active Pharmaceutical Ingredient (API) |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, isigubhu seCardboard, 25kg/Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni, umswakama kanye nezinambuzane.
I-Shanghai Ruifu Chemical Co., Ltd. ingumkhiqizi oholayo kanye nomphakeli we-Revaprazan Hydrochloride (CAS: 178307-42-1) enekhwalithi ephezulu.I-Revaprazan Hydrochloride yehlisa isisho se-COX-2 futhi inezenzo ezibalulekile zokulwa nokuvuvukala ekuthelelekeni kwe-H. pylori.I-Revaprazan Hydrochloride ekwelapheni isilonda se-duodenal, isilonda esiswini kanye ne-gastritis.
I-Revaprazan Hydrochloride (eyaziwa nangokuthi i-reversible proton pump inhibitors, i-potassium competitive acid blockers, i-p-CABs) iyisizukulwane esisha se-proton pump inhibitors ehlehliswayo kanye nokuwukuphela kwe-potassium competitive acid pump inhibitors noma ama-acid pump antagonists emhlabeni.Ithuthukiswe inkampani yaseNingizimu Korea i-Yuhan futhi enamalungelo obunikazi bobunikazi bobunikazi, i-GLAxoSmithKline ithole amalayisense omhlaba wonke okuthuthukiswa nokumaketha komuthi ngaphandle kweNingizimu Korea neNyakatho Korea.Umuthi wagunyazwa yi-FDA yaseNingizimu Korea ngo-2007 ukwelapha izilonda ze-duodenal kanye ne-gastritis.